AEterna Zentaris Inc. (NASDAQ:AEZS) (TSE:AEZ) shares saw strong trading volume on Thursday . 9,290,337 shares were traded during mid-day trading, an increase of 795% from the previous session’s volume of 1,038,324 shares.The stock last traded at $2.70 and had previously closed at $2.01.
Several research analysts have recently issued reports on the company. Maxim Group set a $4.00 price objective on AEterna Zentaris and gave the company a “buy” rating in a research note on Thursday. HC Wainwright set a $3.00 price objective on AEterna Zentaris and gave the company a “buy” rating in a research note on Wednesday, November 29th. Finally, ValuEngine raised AEterna Zentaris from a “strong sell” rating to a “sell” rating in a research note on Friday, September 1st. One research analyst has rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the company. AEterna Zentaris has an average rating of “Hold” and an average price target of $4.33.
An institutional investor recently raised its position in AEterna Zentaris stock. JPMorgan Chase & Co. raised its position in shares of AEterna Zentaris Inc. (NASDAQ:AEZS) (TSE:AEZ) by 451.5% in the third quarter, according to its most recent filing with the SEC. The firm owned 56,800 shares of the biopharmaceutical company’s stock after purchasing an additional 46,500 shares during the quarter. JPMorgan Chase & Co. owned approximately 0.35% of AEterna Zentaris worth $120,000 at the end of the most recent quarter. 2.01% of the stock is owned by institutional investors.
AEterna Zentaris Company Profile
Aeterna Zentaris Inc is a specialty biopharmaceutical company engaged in developing and commercializing treatments in oncology, endocrinology and women’s health. The Company operates through the biopharmaceutical segment. The Company is engaged in drug development activities and in the promotion of products for others.
Receive News & Ratings for AEterna Zentaris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AEterna Zentaris and related companies with MarketBeat.com's FREE daily email newsletter.